Bacterial infections particularly osteomyelitis have become one of the most prominent challenges for orthopaedic surgeries. The treatment of osteomyelitis requires the sequence of debridement, foreign body removal and antibiotic therapy. In this regard, to develop an appropriate drug delivery system a novel calcium phosphate nanocomposite cement was synthesised and loaded with cloxacillin drug against an osteomyelitis agent. Chemical and structural properties of the cement were analysed by X-ray diffraction, Fourier transform infrared spectroscopy and field emission scanning electron microscopy. Antibiotic release assay was conducted to obtain the rate and total time of release in different primary doses. The results showed that by increasing the amount of drug dose in the structure of the cement the release rate is reduced and subsequently sustain drug release with the effective concentration is obtained. Generally, effective bacterial growth inhibition and sustain release is indicative of the suitability of this nanocomposite cement for treating osteomyelitis.
BhattacharyaR, KunduB, NandiSK, Systematic approach to treat chronic osteomyelitis through localized drug delivery system: bench to bed side. Mater Sci Eng C Mater Biol Appl. 2013;33:3986–3993. doi: 10.1016/j.msec.2013.05.036
2.
TsourvakasS.Local antibiotic therapy in the treatment of bone and soft tissue infections. Selected topics in plastic reconstructive surgery. Rijeka: Intech publisher; 2012.
3.
SoundrapandianC, SaB, DattaS.Organic–inorganic composites for bone drug delivery. AAPS Pharm Sci Tech. 2009;10:1158–1171. doi: 10.1208/s12249-009-9308-0
4.
Samit KumarN, PrasenjitM, SubhasisRB, Local antibiotic delivery systems for the treatment of osteomyelitis – a review. Mater Sci Eng C. 2009;29:2478–2485. doi: 10.1016/j.msec.2009.07.014
5.
GitelisS, BrebachGT.The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthop Surg (Hong Kong). 2002;10:53–60. doi: 10.1177/230949900201000110
6.
PerryCR, PearsonRL.Local antibiotic delivery in the treatment of bone and joint infections. Clin Orthop Relat Res. 1991;263: 215–226.
MendelV, SimanowskiHJ, ScholzHC, Therapy with gentamicin-PMMA beads, gentamicin-collagen sponge, and cefazolin for experimental osteomyelitis due to Staphylococcus aureus in rats. Arch Orthop Trauma Surg. 2005;125:363–368. doi: 10.1007/s00402-004-0774-2
9.
ZalavrasCG, PatzakisMJ, HoltomP.Local antibiotic therapy in the treatment of open fractures and osteomyelitis. Clin Orthop Relat Res. 2004;427: 86–93. doi: 10.1097/01.blo.0000143571.18892.8d
10.
JoostenU, JoistA, GoshegerG, Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced chronic osteomyelitis. Biomaterials. 2005;26:5251–5258. doi: 10.1016/j.biomaterials.2005.01.001
11.
NelsonCL, McLarenSG, SkinnerRA, The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. J Orthop Res. 2002;20:643–647. doi: 10.1016/S0736-0266(01)00133-4
12.
DingH, ZhaoCJ, CuiX, A novel injectable borate bioactive glass cement as an antibiotic delivery vehicle for treating osteomyelitis. PLoS One. 2014;9:e85472. doi: 10.1371/journal.pone.0085472
13.
CiernyG.Infected tibial nonunions (1981–1995). The evolution of change. Clin Orthop Relat Res. 1999;360: 97–105. doi: 10.1097/00003086-199903000-00012
14.
NeutD, van de BeltH, van HornJRResidual gentamicin-release from antibiotic-loaded polymethylmethacrylate beads after 5 years of implantation. Biomaterials2003;24:1829–1831.
15.
PapagelopoulosPJ, MavrogenisAF, TsiodrasS, Calcium sulphate delivery system with tobramycin for the treatment of chronic calcaneal osteomyelitis. J Int Med Res. 2006;34:704–712. doi: 10.1177/147323000603400618
16.
DionA, LangmanM, HallG, Vancomycin release behaviour from amorphous calcium polyphosphate matrices intended for osteomyelitis treatment. Biomaterials. 2005;26:7276–7285. doi: 10.1016/j.biomaterials.2005.05.072
17.
SeyfooriA, Mahmoodzadeh HosseiniH, Imani FooladiAASynthesize and characterization of hollow hydroxyapatite nanopowders with different morphologies: role of cationic and non-ionic surfactants. 2014.
18.
CarrodeguasRG, De AzaS.α-Tricalcium phosphate: synthesis, properties and biomedical applications. Acta Biomater. 2011;7:3536–3546. doi: 10.1016/j.actbio.2011.06.019
19.
MontufarEB, TraykovaT, SchachtE, Self-hardening calcium deficient hydroxyapatite/gelatine foams for bone regeneration. J Mater Sci Mater Med. 2010;21:863–869. doi: 10.1007/s10856-009-3918-7
20.
TofighiA, MounicS, ChakravarthyP, Setting reactions involved in injectable cements based on amorphous calcium phosphate. Key Eng Mater. 2000;192:769–772.
21.
MurphyCM, O'BrienFJ.Understanding the effect of mean pore size on cell activity in collagen-glycosaminoglycan scaffolds. Cell Adh Migr. 2010;4:377–381. doi: 10.4161/cam.4.3.11747
22.
BakhtiariL, RezaieHRH, ShokrgozarMA.Investigation of biphasic calcium phosphate/gelatin nanocomposite scaffolds as a bone tissue engineering. Ceram Int. 2010;36:2421–2426. doi: 10.1016/j.ceramint.2010.07.012
23.
SuWY, ChenYC, LinFH.A new type of biphasic calcium phosphate cement as a gentamicin carrier for osteomyelitis. Evid Based Compl Alt Med. 2013;2013:1–9.
24.
AlkhraisatMH, RuedaC, Cabrejos-AzamaJ, Loading and release of doxycycline hyclate from strontium-substituted calcium phosphate cement. Acta Biomater. 2010;6:1522–1528. doi: 10.1016/j.actbio.2009.10.043
25.
MartinA.Physical pharmacy. New Delhi: B. I. Waverly. Pvt Ltd; 1993.
26.
RitgerPL, PeppasNA.A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release. 1987;5:37–42. doi: 10.1016/0168-3659(87)90035-6
27.
GutmannF, KeyzerH.Modern bioelectrochemistry. New York (NY): Springer; 1986.
28.
GaihreB, KhilMS, KangHK, Bioactivity of gelatin coated magnetic iron oxide nanoparticles: in vitro evaluation. J Mater Sci Mater Med. 2009;20:573–581. doi: 10.1007/s10856-008-3565-4
29.
SiepmannJ, PeppasNA.Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48:139–157. doi: 10.1016/S0169-409X(01)00112-0
